![CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/2001025641/2003896921/gr1.gif)
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology
![Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies](http://www.tropicalgastro.com/uploads/Untitlnkged-30.jpg)
Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies
![CA 19–9 levels are increased in the serum of stage II, III, and IV PDAC... | Download Scientific Diagram CA 19–9 levels are increased in the serum of stage II, III, and IV PDAC... | Download Scientific Diagram](https://www.researchgate.net/publication/272943196/figure/fig6/AS:341559015952392@1458445423794/CA-19-9-levels-are-increased-in-the-serum-of-stage-II-III-and-IV-PDAC-patients-CA-19-9.png)
CA 19–9 levels are increased in the serum of stage II, III, and IV PDAC... | Download Scientific Diagram
![The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology](https://cdn.amegroups.cn/journals/pbpc/files/journals/1/articles/181/public/181-PB15-4535-R1.png/w300)
The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology
![Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases | Scientific Reports Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-020-65720-8/MediaObjects/41598_2020_65720_Fig3_HTML.png)
Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases | Scientific Reports
![Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer - ScienceDirect Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1365182X15311230-gr1.jpg)
Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer - ScienceDirect
![Median overall survival according to CA 19-9 serum level baseline level. | Download Scientific Diagram Median overall survival according to CA 19-9 serum level baseline level. | Download Scientific Diagram](https://www.researchgate.net/publication/240307282/figure/fig1/AS:216448275357696@1428616698105/Median-overall-survival-according-to-CA-19-9-serum-level-baseline-level.png)
Median overall survival according to CA 19-9 serum level baseline level. | Download Scientific Diagram
Clinical Significance and Revisiting the Meaning of CA 19-9 Blood Level Before and After the Treatment of Pancreatic Ductal Adenocarcinoma: Analysis of 1,446 Patients from the Pancreatic Cancer Cohort in a Single
![Further evidence of the prognostic role of pretreatment levels of CA 19-9 in advanced pancreatic cancer Further evidence of the prognostic role of pretreatment levels of CA 19-9 in advanced pancreatic cancer](http://old.scielo.br/img/revistas/ramb/v56n1/10t01.gif)
Further evidence of the prognostic role of pretreatment levels of CA 19-9 in advanced pancreatic cancer
![Patients with normal‑range CA19‑9 levels represent a distinct subgroup of pancreatic cancer patients Patients with normal‑range CA19‑9 levels represent a distinct subgroup of pancreatic cancer patients](https://www.spandidos-publications.com/article_images/ol/13/2/ol-13-02-0881-g00.jpg)